HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICCVAM, NICEATM Request Info On Non-Animal Testing; June Deadlines Set

This article was originally published in The Rose Sheet

Executive Summary

Input is requested on the use of topical anesthetics and systemic analgesics during in vivo eye irritation testing and on the murine local lymph node assay for predicting sensitization potential as part of a federal initiative to reduce, refine and replace toxicological tests performed on animals

You may also be interested in...



ICCVAM Plans Next Steps Toward Reducing Animal Use In Toxicity Testing

Two federal agencies charged with reducing, refining and replacing the use of animals in U.S. toxicology testing have released a draft plan that, beginning in 2008, will guide their efforts over the next five years

SACATM Examines Federal Five-Year Plan For Non-Animal Toxicity Research

The Scientific Advisory Committee on Alternative Toxicological Methods considered a proposed federal research priority ranking for the development of non-animal-based approaches to toxicity testing at a Nov. 30 meeting in Research Triangle Park, N.C

Unilever’s Dove Recommits To ‘Real Women’ Against Rising AI Threat

Unilever PLC’s Dove and Baby Dove brands continue tackling prominent social causes with a vow to be responsible about representing women realistically in advertising in the age of AI and a renewed commitment to closing the Black maternal care gap.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel